Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Technology evaluation: HIVAC-1e.

R Zheng1

  • 1St Bartholomew's Hospital, Dept of Immunology, University of London, 38 Little Britain, London, UK. r.q.zheng@mds.qmw.ac.uk

Current Opinion in Molecular Therapeutics
|March 16, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Punishments Enhance Reward Learning by Modulating Striatal Prediction Errors.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2026
Same author

The Ontogeny of Mouse Salivary Gland Macrophages Is Distinct between Sexes.

Journal of dental research·2026
Same author

[Repair of postoperative defects following orbital tumors resection using 3D-printed preformed titanium meshes: a multicenter long-term retrospective study].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2025
Same author

[Research progress in diabetic lumbosacral radiculoplexus neuropathy].

Zhonghua nei ke za zhi·2025
Same author

[Knowledge, attitude and practice of salt reduction and hypertension status and related factors among restaurant practitioners in Beijing City].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex With Men: The DREAM ATN Study (ATN 163).

The Journal of infectious diseases·2025
Same journal

Gene therapy: Have the risks associated with viral vectors been solved?

Current opinion in molecular therapeutics·2011
Same journal

Teduglutide, a glucagon-like peptide-2 analog for the treatment of gastrointestinal diseases, including short bowel syndrome.

Current opinion in molecular therapeutics·2010
Same journal

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Current opinion in molecular therapeutics·2010
Same journal

Corticorelin, a synthetic human corticotropin-releasing factor analog, for the treatment of peritumoral brain edema.

Current opinion in molecular therapeutics·2010
Same journal

Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma.

Current opinion in molecular therapeutics·2010
Same journal

Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease.

Current opinion in molecular therapeutics·2010
See all related articles

Bristol-Myers Squibb

Area of Science:

  • Immunology
  • Vaccinology
  • Virology

Background:

  • Human Immunodeficiency Virus (HIV) infection remains a significant global health challenge.
  • Developing effective vaccines against HIV is a critical research priority.
  • Recombinant viral vectors offer a promising platform for vaccine development.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of HIVAC-1e, a novel HIV-1 vaccine candidate.
  • To assess the antibody responses generated by priming with HIVAC-1e followed by a gp160 booster.
  • To explore the role of HIVAC-1e priming in determining the characteristics of antibody responses.

Main Methods:

  • Phase I clinical trials were conducted in vaccinia-naïve volunteers.
  • Volunteers received an initial vaccination with HIVAC-1e (recombinant vaccinia virus expressing HIV-1 gp160).

Related Experiment Videos

  • A booster vaccination was administered using baculovirus-derived gp160 (VaxSyn).
  • HIV-1 specific IgG antibody titers and epitope specificity were measured post-boosting.

    • Main Results:

    • HIVAC-1e vaccination followed by a gp160 booster elicited HIV-1 specific IgG antibodies in all volunteers.
    • Antibody titers ranged from 1:40 to 1:1280.
    • Priming with HIVAC-1e was identified as a critical factor influencing the magnitude and epitope specificity of the antibody response to gp160.

    Conclusions:

    • The HIVAC-1e vaccine candidate, when used in a prime-boost strategy, successfully induced HIV-1 specific antibodies.
    • The findings support the potential of HIVAC-1e as a component of an HIV vaccine regimen.
    • Further investigation is warranted to assess the efficacy and long-term immune responses.